EMAIL THIS PAGE TO A FRIEND

The American journal of gastroenterology

B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid.


PMID 23649186

Abstract

Rituximab, an anti-CD20 monoclonal antibody that selectively depletes B cells, has shown promise in autoantibody-associated, immune-mediated disorders. As ursodeoxycholic acid (UDCA) is not successful in all patients with primary biliary cirrhosis (PBC), additional treatment options are necessary. The objective of this study was to assess the safety and efficacy of rituximab in patients with PBC refractory to UDCA. Fourteen PBC patients refractory to UDCA received two rituximab infusions (1,000 mg) 2 weeks apart. The primary efficacy outcome was normalization and/or 25% improvement in serum alkaline phosphatase (ALP) concentration at 6 months. The median age was 53 years, and 92% were female and antimitochondrial antibody (AMA) positive. The median UDCA dosage was 15.3 mg/kg/day (interquartile range 14.5-17.8). Although rituximab was well tolerated, one patient withdrew due to an asthma exacerbation during the first infusion. Effective B-cell depletion was observed in the remaining 13 patients, including three that developed human anti-chimeric antibodies. ALP normalization and/or ≥ 25% improvement was observed in three patients (23%) at 6, 12, and 18 months. Significant reductions in median ALP (from 259 U/l at baseline to 213 U/l at 6 months; median decrease 16%), and serum IgM and AMA levels were observed at 6 months. Although fatigue was stable, pruritus improved in 60% of patients at 12 months (vs. 8% with worsening pruritus). Selective B-cell depletion with rituximab was safe and associated with a significant decrease in autoantibody production, but had limited biochemical efficacy in PBC patients with an incomplete response to UDCA.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

P8361 Phosphatase, Alkaline bovine, recombinant, expressed in Pichia pastoris, ≥4000 units/mg protein
P0114
Phosphatase, Alkaline from bovine intestinal mucosa, BioUltra, buffered aqueous glycerol solution, ≥6,500 DEA units/mg protein
A2356
Phosphatase, Alkaline from bovine intestinal mucosa, buffered aqueous glycerol solution, ≥5,500 DEA units/mg protein
P7923
Phosphatase, Alkaline from bovine intestinal mucosa, buffered aqueous glycerol solution, ≥4,000 DEA units/mg protein
P6774
Phosphatase, Alkaline from bovine intestinal mucosa, buffered aqueous solution, 2,000-4,000 DEA units/mg protein
P7640
Phosphatase, Alkaline from bovine intestinal mucosa, lyophilized powder, ≥10 DEA units/mg solid
P4653 Phosphatase, Alkaline from bovine kidney, lyophilized powder, ≥5 units/mg protein (Activity determined in diethanolamine buffer, pH 9.8)
P4978 Phosphatase, Alkaline from calf intestine, buffered aqueous glycerol solution
P4252 Phosphatase, Alkaline from Escherichia coli, ammonium sulfate suspension, 30-90 units/mg protein (modified Warburg-Christian, in glycine buffer)
P4069 Phosphatase, Alkaline from Escherichia coli, buffered aqueous glycerol solution, 20-50 units/mg protein (in glycine buffer)
P5931 Phosphatase, Alkaline from Escherichia coli, lyophilized powder, 30-60 units/mg protein (in glycine buffer)
P3895 Phosphatase, Alkaline from human placenta, ≥10 units/mg solid (in glycine buffer)
P4002 Phosphatase, Alkaline from porcine intestinal mucosa, ≥1 unit/mg solid (in glycine buffer)
P4439 Phosphatase, Alkaline from porcine kidney, lyophilized powder, ≥100 DEA units/mg protein
P2265 Phosphatase, Alkaline from rabbit intestine, 0.2-0.6 unit/mg solid (in glycine buffer)
A2237 Phosphatase, Alkaline shrimp, ≥1,000 DEA units/mL, buffered aqueous glycerol solution, recombinant, expressed in proprietary host
U5127
Ursodeoxycholic acid, ≥99%
C24H40O4
U0800000
Ursodeoxycholic acid, European Pharmacopoeia (EP) Reference Standard
C24H40O4
Y0001163
Ursodeoxycholic acid for system suitability, European Pharmacopoeia (EP) Reference Standard
C24H40O4